COVID-19 and Asthma: Reflection During the Pandemic.

Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and abnormal, overactivated innate immunity and "cytokine storms" have been proposed as potential pathological mechanisms for rapid COVID-19 progression. Theoretically, asthmatic patients should have increased susceptibility and severity for SARS-CoV-2 infection due to a deficient antiviral immune response and the tendency for exacerbation elicited by common respiratory viruses. However, existing studies have not shown an expected prevalence of asthmatic individuals among COVID-19 patients. Certain aspects of type 2 immune response, including type 2 cytokines (IL-4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19. Furthermore, conventional therapeutics for asthma, including inhaled corticosteroids, allergen immunotherapy (AIT), and anti-IgE monoclonal antibody, might also reduce the risks of asthmatics suffering infection of the virus through alleviating inflammation or enhancing antiviral defense. The interactions between COVID-19 and asthma deserve further attention and clarification.

Introduction

Coronaviruses (CoVs) are the largest known positive-sense RNA viruses, with a wide range of hosts, and have seriously affected human and animal health. CoVs known to infect humans include low-pathogenicity CoVs (CoV-229E, CoV-NL63, CoV-OC43, and CoV-HKU1) usually causing mild to moderate illness and high-pathogenicity CoVs that can lead to severe, potentially lethal diseases. In the twenty-first century, outbreaks of infections with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused massive impacts on public health as well as socioeconomic aspects. Notably, the pandemic of coronavirus disease 2019 (COVID-19) caused by the novel CoV severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to global health since December 2019. According to the World Health Organization, there are 3,090,445 reported cases and 217,769 deaths up to 30 April 2020, 08:00 GMT+8. The numbers are still rising rapidly.

Virologically, SARS-CoV-2, sharing 79.6% sequence identity with SARS-CoV and 96% with a bat CoV [1], belongs to the beta-coronavirus family, which also includes SARS-CoV and MERS-CoV. It has been believed that SARS-CoV-2 spreads predominantly by droplets, aerosols, and contact transmission and can also be detected in stool, urine, and blood [2, 3], although how the virus gets there remains a mystery. The majority of infected people have mild or no symptoms, but a proportion of patients display severe and rapid progression of the disease, leading to acute lung injury/acute respiratory distress syndrome and/or multiple organ failure [4, 5]. The median incubation period is estimated to be 5.1 days, with 97.5% of symptomatic infections becoming evident within 11.5 days [6]. The most common symptoms include fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%) [7]. Laboratory examinations have shown that severe COVID-19 patients have decreased numbers of neutrophils, lymphocytes, and eosinophils and neutrophil-to-lymphocyte ratios, suggesting that abnormal, overactivated immune immunity might be a possible mechanism.

Although their exceptionally large genomes enable CoVs to optimize the environment for replication by interacting with host cells [8], host factors are essential in the pathogenesis of CoV infection. It is recognized that compared with others, people with underlying diseases, including hypertension, diabetes mellitus, and cardiovascular and cerebrovascular diseases, more easily develop severe illness and have a worse prognosis [9]. In contrast, asthma, with a high prevalence (estimated 4.2% in the Chinese population [10] and 8.4% in the USA [11]) and potentially pathological changes in the respiratory system, has not been adequately documented in people suffering from COVID-19. Considering the relatively high prevalence of asthma, it is reasonable to hypothesize that asthmatic individuals are relatively resistant to COVID-19 because of the features of the disease and/or the conventional treatment for asthma. The following discusses how asthma patients protect themselves from the virus infection pandemic and how asthma affects COVID-19 susceptibility and the disease course. All of these aspects should be carefully examined.

However, the current understanding of the interactions between CoVs and asthma is still in the early stages, while observational and experimental data are still awaited to elucidate the relationship between COVID-19 and asthma. The purpose of this review is to summarize the current understanding of the possible interactions between these disease entities and to discuss the potential protective effects of asthma therapeutics in the context of COVID-19.

The Pathophysiology of COVID-19

SARS-CoV-2 enters the host cell through targeting angiotensin-converting enzyme II (ACE2), the same receptor as SARS-CoV [1], which might further trigger host immune responses based on previous knowledge of CoVs. After entering the cytoplasm, SARS-CoV releases genomic RNA and begins replication in the host cell. The presence of double-stranded RNA (dsRNA) can elicit an innate immune response through sensitizing Toll-like receptor (TLR)-3 and then activating type 1 interferon (IFN) production by signalling pathway cascades [12]. Type 1 IFNs are important antiviral cytokines that can induce the expression of interferon-stimulated genes (ISGs) [8]. On the other hand, the spike protein (S protein) of the virus might be recognized by TLR-4 and lead to activation of pro-inflammatory cytokines through the MyD88-dependent signalling pathway, recruiting lymphocytes and leukocytes to the infection site [8]. Regarding adaptive immune responses, CoV antigens are presented to T cells by antigen-presenting cells (APCs), which leads to T cell activation and differentiation [12]. This process, which may be accompanied by massive release of pro-inflammatory cytokines, is vital for viral clearance but has the potential to induce overactivated inflammation.

Orchestration between the innate and adaptive immune systems is essential in antiviral responses. If adaptive immune responses are insufficient to eliminate the virus, innate immune responses are likely to be reinforced, which may lead to uncontrollable inflammation [13]. Accumulating evidence derived from COVID-19 patients leads to a putative mechanism of a cytokine storm, which is based on an elevated pro-inflammatory cytokine profile resembling a cytokine storm, especially in severe patients [14]. In a study, Huang et al. measured multiple cytokines in 41 COVID-19 patients (including 13 ICU patients and 28 non-ICU patients) and found that there were higher levels of interleukin (IL)-1β, IL-1Rα, IL-7, IL-8, IL-9, IL-10, basic fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), IFN-γ, interferon-γ-inducible protein (IP-10), monocyte chemoattractant protein (MCP-1), macrophage inflammatory protein 1 alpha (MIP-1α), macrophage inflammatory protein 1 beta (MIP-1β), platelet-derived growth factor (PDGF), tumor necrosis factor (TNF-α), and vascular endothelial growth factor (VEGF) in COVID-19 patients than in healthy controls [4]. The same authors have also noted that there were higher concentrations of IL-2, IL-7, IL-10, G-CSF, IP-10, MCP-1, MIP-1α, and TNF-α in ICU patients than in non-ICU patients [4]. In addition, significant elevation of IL-6 levels, especially in severe patients, has been reported in several studies [15-19]. Cytokines reported to be altered in COVID-19 patients are summarized in Table 1.

Table 1

Cytokine profiles reported in COVID-19 patients

Cytokines or chemokines	Changes in COVID-19	References
IL-1β	Increase in COVID-19 patients	[4]
	Undetectable in COVID-19 patients	[16]
IL-1Rα	Increase in COVID-19 patients	[4]
IL-2	Increase in severe COVID-19 patients	[4]
	No significant change	[17]
IL-2R	Increase in severe COVID-19 patients	[15]
IL-4	Increase in severe COVID-19 patients	[4]
	No significant change	[17, 20]
IL-5	No significant change compared to healthy controls	[4]
IL-6	Increase in severe COVID-19 patients	[4, 20]
	Increase in COVID-19 patients, higher in severe patients	[15–18]
IL-7	Increase in COVID-19 patients, higher in severe patients	[4]
IL-8 (CXCL8)	Increase in COVID-19 patients	[4]
	Within normal range	[15]
IL-9	Increase in COVID-19 patients	[4]
IL-10	Increase in COVID-19 patients, higher in severe patients	[4, 17]
	Increase in severe COVID-19 patients	[15]
	Within normal range	[20]
IL-12 (p70)	No significant change	[4]
IL-13	Increase in severe COVID-19 patients	[4]
IL-15	No significant change	[4]
IL-17	Increase in severe COVID-19 patients	[4]
	Within normal range	[20]
Eotaxin (CCL11)	No significant change	[4]
Basic FGF	Increase in COVID-19 patients	[4]
G-CSF	Increase in COVID-19 patients, higher in severe patients	[4]
GM-CSF	Increase in COVID-19 patients	[4]
IFNγ	Increase in COVID-19 patients	[4]
	No significant change	[17]
IP10 (CXCL10)	Increase in COVID-19 patients, higher in severe patients	[4]
MCP-1 (CCL2)	Increase in COVID-19 patients, higher in severe patients	[4]
MIP-1α (CCL3)	Increase in COVID-19 patients, higher in severe patients	[4]
MIP-1β (CCL4)	Increase in COVID-19 patients	[4]
PDGF	Increase in COVID-19 patients	[4]
RANTES (CCL5)	No significant change	[4]
TNF-α	Increase in COVID-19 patients, higher in severe patients	[4]
	Increase in severe COVID-19 patients	[4, 15, 17]
VEGF-α	Increase in COVID-19 patients	[4]

IL, interleukin; CXCL, chemokine (C-X-C motif) ligand; CCL, C-C motif chemokine; FGF, fibroblast growth factor; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-monocyte colony-stimulating factor; IFN, interferon; IP10, interferon-γ inducible protein 10; MCP-1, monocyte chemo-attractant protein 1; MIP1-α, macrophage inflammatory protein 1-α; MIP1-β, macrophage inflammatory protein 1-β; PDGF, platelet-derived growth factor; RANTES, Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted; TNF-α, tumor necrosis factor α; VEGF, vascular endothelial growth factor

It has been proposed that severe COVID-19 patients have a cytokine profile resembling secondary hemophagocytic lymphohistiocytosis (sHLH), accompanying rapid progression of lung injury and multiorgan damage [20]. Moreover, there are notable signs showing immune system damage manifesting as extreme lymphopenia and spleen and lymph node atrophy in severe COVID-19 patients [14]. Currently, some anti-inflammatory drugs, including glucocorticoids, tocilizumab (TCZ, an anti-human IL-6 monoclonal antibody), and Janus kinase (JAK) inhibitors, have been applied in COVID-19 therapy but await additional clinical evidence to evaluate safety and efficacy.

The pathological understanding of COVID-19 is still growing. The first published pathological report generated in 2 patients from Wuhan, China, showed edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration and multinucleated giant cells, suggesting early phase pulmonary changes [21]. Investigation of a patient who died of severe COVID-19 revealed evident desquamation of pneumocytes and hyaline membrane formation, which are similar to what was observed in SARS and MERS [22]. Other pathological examinations derived from 2 fatal COVID-19 cases in Wuhan, China, showed that there were mucous plugs with fibrinous exudate in the alveoli and activation of alveolar macrophages because these macrophages had strong expression of IL-10 and programmed death-ligand 1 (PD-L1) and moderate expression of IL-6 and TNF-α [23].

The Pathophysiology of Asthma

Asthma is a common respiratory disease characterized by airway chronic inflammation, mucus overproduction, hyperresponsiveness, and remodelling. Normally, the majority of the disease is predominantly mediated by type 2 immune responses. The type 2 immune response involves T helper (Th) 2 cells, type 2 B cells, group 2 innate lymphoid cells, type 2 macrophages, IL-4-secreting nature killer (NK) and natural killer T (NKT) cells, basophils, eosinophils, and mast cells [24]. A variety of cytokines produced by immune system and epithelial cells contribute to the regulatory network. For example, IL-4 and IL-13 have essential roles in allergen-specific immunoglobin (Ig) E production and accumulation of Th2 cells and eosinophils in local tissues, as well as epithelial barrier regulation, while IL-5, IL-9, and IL-13 contribute to eosinophilia and mucus production [25].

Pre-existing Asthma and COVID-19

Deficient Antiviral Response in Asthmatic Patients

It is generally acknowledged that antiviral and allergic responses are two distinct arms in immunity and are reciprocally regulated, involving a comprehensive interaction network [26]. IFNs, a family of important antiviral cytokines, play a central role in this regulatory network. It has been proposed that individuals with asthma are predisposed to allergic responses that might override the antiviral response, manifesting as elevated susceptibility and a deficient immune response to viral infection [26].

Previous studies have shown that IFN production by bronchial epithelial cells and plasmacytoid dendritic cells (pDCs) is impaired in asthmatic individuals [27-30]. It has also been shown that there is reduced production of IFN-β in asthmatic bronchial epithelial cells, accounting for impaired apoptosis and increased rhinovirus (RV) replication [27]. Deficient IFN-α/β expression by bronchial epithelial cells has also been noted in asthmatic patients after RV infection, which is associated with increased viral load and adverse clinical outcomes [28]. In addition, deficient induction of IFN-λ by RV in bronchial epithelial cells and alveolar macrophages has also been observed in vivo, which is highly correlated with the viral load and severity of asthma exacerbations [29]. Upon exposure to influenza A, pDCs from asthmatic patients produce less IFN-α than those from healthy controls [30].

Furthermore, IgE cross-linking, a hallmark of allergic diseases, is able to dampen antiviral immune responses through abrogating the IFN-α response, diminishing TLR-7 upregulation, and interrupting pDC maturation [30], while concentrations of serum IgE are inversely correlated with a reduction in IFN-α secretion [30]. These observations collectively suggest a possible mechanism of the impaired antiviral response in asthmatic patients. Although most experimental studies are performed in RV or influenza infection models, which are the most common respiratory viruses in asthma exacerbations, these findings still display a general pattern of antiviral responses. Another thing worth noting is that the expression of IFNs is comparable to that in healthy controls when atopic diseases are mild or easily controlled [30], indicating the importance of controlling disease activity.

It should also be noted that CoVs can shield themselves from cytosol sensors and actively counteract host innate immune responses [8]. For example, the dephosphorylation and deubiquitination ability of SARS-CoV is able to inhibit IFN signalling [31, 32]. It is difficult to estimate to what degree the innate immune response would be reduced during CoV infection in asthmatic individuals. However, considering that the pathogenesis of SARS is often associated with abnormal, overactivated innate immunity [32], the influence of an attenuated immune response on the disease course of SARS-CoV-2 infection may be comprehensive and individualized.

CoV Infection and Eosinophil Inflammation

It is well known that eosinophils play a central role in allergic diseases, including asthma. The potential effects of eosinophils on CoV are also noteworthy. Previous experimental studies have indicated a potential role of eosinophils in promoting viral clearance and antiviral host defense, although this phenomenon is not observed in all circumstances [33]. In vitro studies have shown that recombinant eosinophil-derived neurotoxin (a major eosinophil ribonuclease) is capable of reducing the infectivity of respiratory syncytial virus (RSV), which can be reversed by a ribonuclease inhibitor [34], suggesting the possibility that eosinophils are able to target the single-stranded RNA (ssRNA) genome of respiratory viruses (such as RSV) with their secretory ribonucleases. In addition, eosinophils can be activated with ssRNA through triggering the TLR-7-MyD88 signalling pathway, which might result in RSV clearance and limitation of virus-induced lung dysfunction [35]. The capacity of eosinophils to protect against viral infection [36] might therefore account for a low prevalence of asthmatic individuals among patients with COVID-19.

Interestingly, some studies have shown eosinopenia in COVID-19 patients, which is more prominent in severe patients than in mild patients [15, 37]. The eosinophil count returns to normal after sustained usage of lopinavir, suggesting that an increase in eosinophils may serve as an indicator of COVID-19 improvement [38]. In addition, eosinopenia has also been reported in SARS-CoV [39, 40] and MERS-CoV infections [41]. However, whether such eosinopenia is the result of generally impaired immunity (including Th2 cells and Th2 cytokine production) or whether it is the result of direct virus targeting still needs to be clarified. Nevertheless, it would be intriguing to explore the role of eosinophils in SARS-CoV-2 infection and the potential influence of allergy-elicited eosinophilic inflammation on the course of COVID-19. For example, we need to know whether pre-existing eosinophilia in asthmatic patients counteracts the reduction of eosinophils during the disease course of COVID-19. Whether tissue infiltration of eosinophils promotes viral clearance and antiviral host defense in asthmatic patients needs to be explored. Further observations, of course, are needed to verify this theoretical protective role of eosinophils in SARS-CoV-2 infection and the potential influence of allergy-elicited eosinophilic inflammation on COVID-19 disease course.

Viral-Induced Asthma Exacerbations

Respiratory virus infection accounts for up to 80% of acute exacerbations of asthma in children and half of such episodes in adults, among which RV is the most common cause [42, 43]. Message et al. have shown that in response to RV infection, asthmatic individuals have increased clinical severity, impaired lung function, bronchial hyperreactivity, and eosinophilic inflammation, which affect the virologic and clinical outcomes, possibly related to augmented Th2 or impaired Th1 or IL-10 responses [44]. CoVs are also detected at a mean prevalence of 8.4% in asthma exacerbations [45]. Most interestingly, there are no reports regarding asthma exacerbation due to COVID-19. Correspondingly, there are few reports on asthma exacerbations during the SARS and MERS epidemics [46]. These phenomena, notably, still need to be well documented.

Are Asthma Patients at an Increased Risk of COVID-19?

Considering that asthmatic patients have impaired immune responses against virus infection and that respiratory viral infections have the potential to trigger or worsen asthma symptoms, the management of asthma patients becomes more complex during the COVID-19 pandemic. Theoretically, it seems that pre-existing asthma has a potential influence on SARS-CoV-2 susceptibility and disease course. However, existing studies have not indicated a high prevalence of asthma among COVID-19 patients. Throughout the published studies on COVID-19, few studies have listed asthma as a comorbidity, which is insufficient to support any solid conclusion. According to the China Centers for Disease Control (CDC), only 2.4% of 44,672 patients had chronic respiratory disease (including asthma) [47]. Another study reported no physician-diagnosed asthma among 1590 patients in China [48]. Gao et al. reported on 140 COVID-19 patients in Wuhan, China, among whom 11.4% were hypersensitive to certain drugs, and 1.4% had urticaria, but no patients had asthma or other allergic diseases [37]. In another case series reported by the same team, patients with common allergic diseases (1 child with allergic rhinitis, 1 child with atopic dermatitis, and 1 adult with chronic urticaria) did not have symptoms distinct from those of other COVID-19 patients and did not develop severe courses [49]. To support this result, the authors also mentioned that they did not find asthma history among pediatric COVID-19 patients (number not known, data unpublished) [49]. A study from Lombardy, Italy has also shown relatively low prevalence of asthma [50]. Only statistics from New York City, USA, shows a 9% prevalence of asthma [51], although there is no clear identification of the precise clinical phenotypes and treatments of the patients included. However, asthma is absent from the top 10 comorbidities according to the fatality statistics of the New York State [52]. These results collectively suggest that allergic diseases may not be a predisposing or aggravating factor for COVID-19. Table 2 summarizes the prevalence of asthma reported in patients with COVID-19.

Table 2

Prevalence of asthma in patients with COVID-19

Population	Number of patients	Mean or median age (years)	Prevalence (%)	Reference
China	44,672	NA	2.4% for chronic respiratory disease (not specified for asthma)	[47]
China	1590	48.9	0%	[48]
Wuhan, China	140	57	0%	[37]
Lombardy, Italy	1591	63	< 3% (not specified)*	[50]
New York City, USA	5700	63	9%	[51]

COVID-19, coronavirus disease 2019. *Comorbidities with prevalence no less than 3% were listed as separate items, while asthma was counted as “others” with unspecified prevalence

Some type 2 cytokines, such as IL-4, IL-13, and IL-9, also have anti-inflammatory effects [53]. For example, IL-4 can not only suppress development of Th1 cells from the Th0 activated stage but also inhibit production of multiple pro-inflammatory cytokines, including IL-1β, TNF-α, IL-6, and IL-12 [54, 55]. It has been also shown that IL-13 has immunoregulatory effects through inhibiting the secretion of pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, and TNF-α) and chemokines (IL-8, MIP-1α and MIP-1β, and monocyte chemotactic protein-3) [56]. Furthermore, IL-9 reduces the secretion of TNF-α and IL-10, but increases the secretion of transforming growth factor beta (TGF-β) on LPS-activated monocytes [57]. It is possible, therefore, that predominance of type 2 cytokines might counteract the accumulation of pro-inflammatory cytokines to some extent, including the pathogenesis of COVID-19.

On the other hand, the expression of ACE2, which is the entry receptor for SARS-CoV-2, might be affected by asthmatic conditions. Through examining the RNA-seq data in airway cells from 3 different cohorts, a recent study has reported that respiratory allergy and controlled allergen exposures are associated with significant reductions in ACE2 expression [58]. Another study has also shown that type I IFNs, and to a lesser extent type II IFNs, upregulate the expression ACE2, indicating that SARS-CoV-2 might exploit host antiviral defense to facilitate its entry into target cells [59]. Considering that higher ACE2 expression increases in vitro susceptibility to SARS-CoV, the general deficient IFN responses in asthmatic patients might reduce the virus invasion, at least partially through limiting the ACE2 expression on the target cells.

Currently, it is still not known whether a distinct type 2 immune response contributes to certain protection of allergic patients from COVID-19. Clearly, wide and large-scale investigations are expected to further elucidate the interactions between COVID-19 and asthma.

Asthma Therapeutics and COVID-19

Additional major concerns are whether therapeutics for asthma (including corticosteroids, allergen-specific immunotherapy (AIT), monoclonal antibodies, leukotriene antagonists, bronchodilators) affect the immune system, which in turn reduces COVID-19 infection, and whether these medications would influence the biological behavior of SARS-CoV-2 in the human body.

Inhaled Corticosteroids

High-dose corticosteroids have been used α during the SARS and MERS outbreaks and in COVID-19 to suppress lung inflammation during critical illness of infected patients. Despite association with delayed viral RNA clearance and increased risks of secondary infections [60], corticosteroid usage has been supported by some studies for benefits that likely outweigh the adverse effects [14, 61]. Since the clinical evidence for the usage of corticosteroids in COVID-19 is still insufficient, the corticosteroids given to COVID-19 patients, only if necessary, should be cautiously administered, with strict restrictions on indications and dosage [62].

However, low-dose inhaled corticosteroids are routinely used by a considerable proportion of asthma patients on a daily basis. One important question is whether inhaled corticosteroids, often along with beta2-agonists and/or muscarinic antagonists, would affect the disease course and severity of COVID-19. Previous studies have indicated that inhaled corticosteroids can reduce pro-inflammatory cytokine levels (including MIP-1α, GM-CSF, TNF-α, and IL-1Rα) and increase anti-inflammatory cytokine levels (IL-10) in asthma patients [63, 64]. It is, therefore, very possible that the low-dose, inhaled corticosteroids exert protective effects on asthma patients by reducing airway inflammation, if any, in the early stage of SARS-CoV infection. In addition, an in vitro experimental study has shown that glycopyrronium, formoterol, and a combination of glycopyrronium, formoterol, and budesonide are capable of reducing HCoV-229E replication, partly by inhibiting receptor expression and/or endosomal function [65]. Considering the difference in the features of the viruses, the results for HCoV-229E should be interpreted cautiously. However, the potential anti-inflammatory and antiviral effects of low-dose, inhaled corticosteroids on asthmatic patients certainly deserve further investigation.

In addition, it has been known that glucocorticoid receptors are essential in determining glucocorticoid responsiveness, while alterations in number, splicing pattern, and epigenetic changes of the receptors may play a role in glucocorticoid-resistant asthma [66]. It is reasonable to speculate that there might also be a difference in severity and disease course of COVID-19 between asthmatic patients who are sensitive or non-sensitive to steroids. Are there any changes in the glucocorticoid receptors which might account for less effectiveness in the treatment with steroids in COVID-19? Whether glucocorticoid receptors play a role in the effectiveness of steroid treatment in COVID-19 deserves to be further clarified.

AIT

AIT has been used in allergic diseases for more than 100 years, and many new therapeutic advances have been introduced in recent years. The underlying mechanisms of AIT include the very early desensitization effect, modulation of T and B cell responses, and prevention of tissue homing and degranulation of allergy effector cells (mast cells, basophils, and eosinophils) [67]. An essential process of AIT is the generation and maintenance of functional allergen-specific regulatory T (Treg) cells and regulatory B (Breg) cells [68]. Treg cells, together with their inhibitory cytokines, such as IL-10 and TGF-β, suppress Th2 immune responses and control allergic inflammation [68]. In addition, it is recognized that Treg cells play a role in preventing cytokine storms and limiting tissue damage [69, 70]. Considering the putative pathomechanism of cytokine storms in severe COVID-19 patients, it is possible that the immune tolerance induced by AIT might have a protective role. Of course, this concept is putative and it necessitates further examination.

Anti-IgE Monoclonal Antibody

As stated earlier, cross-linking IgE-FcεRI (its high affinity receptor) dampens antiviral responses in asthmatic patients, which has led to research on anti-IgE monoclonal antibodies. Since 2003, omalizumab, a monoclonal antibody against human IgE, has been approved for the treatment of severe, persistent asthma. As expected, recent studies have shown that blocking IgE could reduce susceptibility to respiratory virus infection through enhancing IFN-α signalling in pDCs [71-73]. In the Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE) study, omalizumab treatment was able to decrease RV infection duration, viral clearance, and RV illness frequency [72]. In a randomized, multicentre clinical trial, omalizumab improved IFN-α signalling in response to RV infection, which was associated with reduced asthma exacerbations [71]. Another study has also shown the effect of omalizumab on increasing pDC IFN-α responses but reducing the expression of pDC FcεRIα in children with asthma [73]. In addition, IL-33 levels decrease after omalizumab treatment [74, 75], which induces the production of pro-inflammatory cytokines (including IL-6, IL-1β, TNF-α, MCP-1, and prostaglandin D2) [76]. Taken together, these observations suggest a potential effect of omalizumab on antiviral responses. It would be intriguing to explore whether previous or concurrent use of omalizumab has potential protective effects on COVID-19 infection, on either duration or severity or both. A putative diagram showing the potential mechanisms by which asthmatic individuals “escape” from COVID-19 is shown in Fig. 1.

Fig. 1

The schematic presentation of putative interactions between COVID-19 and asthma

Considering the potential protective effects of asthma therapeutics, and the increased risk of nosocomial infections with exacerbations, we recommend that asthmatic patients continue taking the prescribed medications during the pandemic.

Conclusion

Despite deficient antiviral immune responses and the tendency for acute exacerbation, there is little evidence showing that asthma patients have increased susceptibility or severity of SARS-CoV-2 infection than others. It is particularly intriguing to explore whether features of the disease, type 2 immune response, asthma therapeutics, or all of them are capable of providing certain protective effects against COVID-19. Notably, further clinical and basic studies are expected to explore the relationship between COVID-19 and asthma and/or other allergic diseases.